MDACC Study No:2006-0018 ( NCT No: NCT00288626)
Title:A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis
Principal Investigator:Uday Popat
Treatment Agent:Antithymocyte Globulin; Autologous CD34+ Hematopoietic Progenitor Cells; Carmustine; Cytarabine; Etoposide; Melphalan
Study Status:Closed
Study Description:The goal of the screening portion of this study is to evaluate your disease
condition and find out if you are eligible to take part in the main study. The
screening evaluation in some cases may change your diagnosis, or confirm the
diagnosis you have previously received. Specific testing on organs such as
your lungs, heart, and brain will be done to confirm that you do not have any
medical abnormalities that would increase your risk from the transplant.
Hide details for General InformationGeneral Information

Disease Group:Other Studies
Phase of Study:Phase II
Treatment Agents:Antithymocyte Globulin
Autologous CD34+ Hematopoietic Progenitor Cells
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:30 days
Supported By:N/A
Return Visit:Weekly for 100 days after transplant. 3 monthly thereafter.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Uday Popat
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-745-3055
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults